Share This Page
Suppliers and packagers for generic pharmaceutical drug: cabazitaxel
✉ Email this page to a colleague
cabazitaxel
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | JEVTANA KIT | cabazitaxel | SOLUTION;INTRAVENOUS | 201023 | NDA | Sanofi-Aventis U.S. LLC | 0024-5824-11 | 1 KIT in 1 CARTON (0024-5824-11) * 5.7 mL in 1 VIAL, GLASS (0024-5823-15) * 5.7 mL in 1 VIAL, GLASS (0024-5822-01) | 2010-06-17 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Cabazitaxel
Introduction
Cabazitaxel, marketed under the brand name Jevtana among others, is a chemotherapeutic agent primarily indicated for metastatic castration-resistant prostate cancer (mCRPC). As a semi-synthetic taxane, cabazitaxel functions by inhibiting microtubule disassembly, thereby disrupting cell division and inducing apoptosis. Given its critical role in oncology treatment regimens, the global supply chain for this drug is pivotal for healthcare providers, pharmaceutical manufacturers, and patients. This article examines the key suppliers involved in the manufacturing, distribution, and supply of cabazitaxel, highlighting their market roles, capabilities, and strategic importance.
Manufacturers of Cabazitaxel
1. Sanofi
Sanofi is the original developer and patent holder for cabazitaxel. The company introduced Jevtana to the market in 2010 after clinical success in treating mCRPC. Sanofi’s manufacturing facilities, primarily based in Europe and the United States, are equipped with advanced biotechnological infrastructure capable of producing high-purity cabazitaxel. As a leading global pharmaceutical company, Sanofi maintains a dominant position as a reliable supplier, leveraging extensive R&D capabilities and manufacturing scale to meet global demand.
2. Piramal Enterprises
Piramal Pharmaceuticals, a division of Piramal Group, is among the prominent generic manufacturers of cabazitaxel. They produce bioequivalent formulations for various markets, particularly focusing on regions with high generic drug consumption such as India, Southeast Asia, and parts of Africa. Piramal’s manufacturing facilities are certified under international standards (e.g., cGMP, EMA, FDA), ensuring product quality and compliance. Piramal’s strategic position as a generic supplier prolongs the availability of cabazitaxel post-patent expiry.
3. Dr. Reddy’s Laboratories
Dr. Reddy’s is an established producer of chemotherapeutic agents, including cabazitaxel. The company has invested in rigorous quality controls and scalable manufacturing to ensure consistent supply. Dr. Reddy’s supplies the drug to both domestic Indian markets and select international territories. Their manufacturing units in India are sanctioned by global regulatory agencies, allowing broad distribution.
4. Jiangsu Hengrui Medicine Co., Ltd.
Chinese biopharmaceutical company Jiangsu Hengrui has emerged as a significant player in the oncology drug market. While primarily known for targeted therapies and monoclonal antibodies, they have also expanded into the production of taxanes, including cabazitaxel. Their facilities adhere to strict international standards, and they supply in Asian markets as well as international ones through strategic partnerships.
Supplier Networks and Distribution
While manufacturing companies are primary suppliers, the global distribution of cabazitaxel involves a complex network of distributors, wholesalers, and logistics providers. The following entities are instrumental in ensuring market availability:
- McKesson Corporation: A leading pharmaceutical distributor in the United States, McKesson sources cabazitaxel from Sanofi and distributes it to hospitals and clinics nationwide.
- Cencora (formerly AmerisourceBergen): Acts as a vital intermediary supplying cabazitaxel to healthcare organizations across North America.
- Meizhou Hongteng Pharmaceutical Co., Ltd.: A regional distributor in China, facilitating the local market supply for Jiangsu Hengrui medicine.
- Regional and local distributors in Europe and Asia: Ensuring timely delivery to remote hospitals and pharmacies, often working under agreements with companies like Sanofi and Dr. Reddy’s.
Factors Affecting Supply Chain Stability
Regulatory approvals, manufacturing capacity, patent status, and market demand significantly influence the stability of cabazitaxel supply. Patent expiration avenues have allowed other generic players to enter the market, increasing supply and potentially reducing costs. However, manufacturing complexities associated with taxanes—marked by their complex extraction and synthesis processes—pose limitations on supply scalability.
Moreover, geopolitical factors, such as export restrictions or supply chain disruptions stemming from global events like COVID-19, can impact availability. Companies with diversified manufacturing bases and regional production facilities mitigate these risks effectively.
Emerging Players and Future Supply Dynamics
The oncology pharmaceutical landscape continues to evolve with novel formulations and biosimilars. Emerging players, especially in Asia, aim to establish themselves as cost-effective suppliers of cabazitaxel. Their entry increases market competition, which can lead to better pricing and supply assurances.
Furthermore, advancements in biotechnological synthesis methods are projected to streamline manufacturing processes, potentially lowering production costs and increasing global supply capacity. Strategic partnerships between Western companies and Asian manufacturers are expected to expand distribution reach.
Regulatory Considerations and Quality Standards
Suppliers must meet stringent regulatory FDA, EMA, and other international standards, which govern manufacturing practices, batch consistency, and safety profiles. Suppliers holding such certifications can access a broader global market, including developed nations, and often enjoy preferential treatment in tendering processes for hospital supplies.
Any lapses in compliance or quality assurance can jeopardize supply and lead to shortages, emphasizing the importance of high-caliber manufacturing infrastructure and rigorous quality controls.
Conclusion
The suppliers of cabazitaxel comprise a mix of originator firms, such as Sanofi, and numerous generic manufacturers, including Piramal, Dr. Reddy’s, and Jiangsu Hengrui. These companies operate within complex distribution networks, ensuring the drug reaches markets worldwide. As patent protections expire and generics enter the market, supply is likely to increase, fostering competitive pricing and broader access.
For stakeholders, understanding the intricacies of manufacturing capabilities, regulatory adherence, and geopolitical impacts remains critical in ensuring stable access to cabazitaxel. Strategic diversification of suppliers and adherence to international standards will remain key drivers of supply chain resilience.
Key Takeaways
- Sanofi remains the primary original manufacturer of cabazitaxel, while several generic firms are active across emerging markets.
- Manufacturing capacity and regulatory compliance are essential for dependable supply; companies with strong GMP standards sustain consistent output.
- Distribution networks operate through major pharmaceutical distributors, ensuring regional market access.
- Patent expirations stimulate generic entry, expanding supply sources and improving affordability.
- Global geopolitical and logistical factors significantly impact supply stability, necessitating diversified manufacturing and distribution strategies.
FAQs
1. What are the leading global suppliers of cabazitaxel?
Sanofi is the original developer and primary supplier. Major generic producers include Piramal Enterprises, Dr. Reddy’s Laboratories, and Jiangsu Hengrui Medicine, all of which serve different regional markets.
2. How does patent expiration affect the supply of cabazitaxel?
Patent expiry opens the market for generic manufacturers, increasing supply, reducing prices, and expanding access. However, it also introduces variability depending on manufacturing capacity and regulatory approval.
3. What regulatory standards must cabazitaxel suppliers meet?
Suppliers must adhere to cGMP (current Good Manufacturing Practice) standards mandated by agencies like the FDA, EMA, and other local regulators to ensure safety, efficacy, and quality.
4. Which regions have the most diversified cabazitaxel supply chains?
The United States and Europe benefit from multiple suppliers and distributors, ensuring supply stability. Many Asian countries depend largely on regional manufacturers and distributors.
5. What is the future outlook for cabazitaxel supply?
The growing market for oncology treatments and the entry of new generic players, along with technological advances in manufacturing, suggest increased supply and potentially lower costs in the coming years.
Sources
- [1] Sanofi Official Website. Cabazitaxel overview.
- [2] Worldwide Market Reports. Oncology drugs market analysis.
- [3] U.S. Food & Drug Administration. Drug manufacturing standards.
- [4] European Medicines Agency. Pharmaceutical product approval and standards.
- [5] Global Oncology Pharmaceutical Landscape. Industry reports and analyses.
More… ↓
